FDA
-
-
-
-
-
-
-
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
-
-
-
-
-
-
-
ARS Pharmaceuticals wins European patent challenge for neffy spray
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

